GE HealthCare to feature latest advancements in diagnostic accuracy and patient-centered breast care at SBI 2025 Breast Cancer Imaging Symposium
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a global leader in breast health technology, will feature its latest advancements in diagnostic accuracy and patient-centered breast care during the 2025 Society of Breast Imaging Symposium in Colorado Springs, Co., April 24-27, 2025. This year's showcase will feature new innovations designed to improve breast cancer detection, streamline workflows, and enhance overall patient care.
Mammography innovations streamline exam workflows for patient-centered breast care
GE HealthCare's latest technologies include the Pristina Via™ mammography system, which provides effortless acquisition, operational excellence, and clinical confidence, which enhances the screening experience for both technologists and patients. This innovation, part of the Senographe Pristina™ platform, provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care.
Pristina Via, developed with technologists in mind, takes in-room workflow and patient comfort to the next level through zero-click acquisition functionality when acquiring within protocols, no wait time between exposures 1, and DBT image-to-image cycle times that are up to twice as fast as other mammography systems on the market. 2 Additionally, Pristina Via delivers vendor-neutral prior image comparison, reducing time spent analyzing previous exams and enabling final assessments more efficiently, and Pristina 3D STD mode has the lowest radiation dose for all thickness among the major systems available in the marketplace. 3,4
GE HealthCare to distribute DeepHealth's SmartMammo™ in the U.S. to streamline radiology workflows
GE HealthCare continues its strategic collaboration with DeepHealth Inc, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of AI in imaging. The latest milestone includes the commercial availability of SmartMammo™, 510(k) cleared for use with Pristina in U.S. markets. GE HealthCare will distribute SmartMammo to imaging providers in the U.S. alongside the Pristina platform, allowing for integration of advanced AI directly into the company's comprehensive breast imaging portfolio.
AI continues to show great promise in breast cancer screening, from early detection and risk prediction to reduced callbacks and more efficient workflows for breast imaging providers. SmartMammo is an AI-powered SaaS solution designed to seamlessly integrate into existing breast cancer diagnostic workflows, enhancing diagnostic accuracy and workflow efficiencies. 5,6. SmartMammo facilitates fast image loading and real-time data rendering of multimodality images, accessible from any workstation and location and integrates directly into the customer's IT stack. DeepHealth's AI-powered breast cancer detection offers automatic lesion localization and degree of suspicion that are effective in diverse populations and dense breast tissue. 5 GE HealthCare's Pristina Via, combined with SmartMammo, provides workflow efficiency for both technologists and radiologists, as well as enhanced image interpretation features with automatic lesion localization.
'We are committed to delivering innovative technologies and end-to-end solutions that address our customer's biggest challenge in breast cancer detection, which is to help clinicians provide efficient, accurate and personalized diagnosis to patients,' says Pooja Pathak, Vice President and General Manager of Mammography at GE HealthCare. 'With Pristina Via and SmartMammo, we have streamlined both exam and radiology workflows in breast cancer screening and diagnostics, enabling clinicians to prioritize patient care.'
Latest advancements for breast cancer detection:
Invenia™ Automated Breast Ultrasound (ABUS) Premium, the first FDA-approved breast ultrasound indicated as an adjunct to mammography and specifically designed for detecting cancer in dense breasts, will also be showcased at the Symposium. According to studies across the U.S. and Europe, 40% of women and 70% of Asian women have dense breast tissue. 7,8 For patients with dense breasts, the addition of ABUS screening when used with mammography has demonstrated a 35.7% increase in cancer detection compared to mammography alone. 9 The latest Invenia ABUS Premium aims to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology. It features new integrated Verisound™ AI and AI Assistant 10, ensuring faster 11 and reproducible scanning and reading with extraordinary image quality. This increases clinical confidence, addresses workflow productivity, and aids in the detection of breast cancer in women with dense breasts.
SenoBright™ HD Contrast Enhanced Mammography (CEM) is a next-level mammogram that helps reduce the masking effect of fibroglandular breast tissue and increases the tumor signal to increase diagnostic confidence. It allows for imaging exams to be conducted in less than seven minutes and enables the detection of lesions that would otherwise go undetected 12, providing patients with answers right away to help them avoid the anxiety of an inconclusive exam.
Serena Bright™ is a contrast guided biopsy system that enables providers to see lesions using CEM and sample with certainty. This allows patients to undergo breast biopsy exams using the same mammography equipment, in a familiar setting, with familiar staff, to help relieve some of the stress of a biopsy procedure.
To learn more about the personalized breast cancer screening solutions GE HealthCare will be featuring at SBI 2025, please visit booth #407.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 Elapsed time between end of an exposure and system ready in DBT is 2.3s. Measured with ACR Phantom. Pristina Via performance measurement. Data on file GE HealthCare 2024.
2 Image to Image cycle time is the minimum waiting time by the System between two consecutive images. Measured with ACR phantoms for Pristina Via compared to claimed performance of competitor (Dimension 3D_ in Product Data Sheet from Jul-2024)
3 Phantom measurements as of July 2024. Senographe Pristina with default value STD mode.
4 Dose comparison based on NHS Breast Screening Programme equipment reports. https://medphys.royalsurrey.nhs.uk/nccpm/?s=technicalreports.
5 U.S. Food and Drug Administration. "Premarket Notification (510k) Summary: K243688." Accessed April 23, 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243688.pdf.
6 Kim, J., et al. "Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists." Radiology: Artificial Intelligence (2024). https://doi.org/10.1148/ryai.230137.
7 Ellison-Loschmann, Lis, et al. 'Interactive and Independent Associations between the Socioeconomic and Objective Built Environment on the Neighbourhood Level and Individual Health: A Systematic Review of Multilevel Studies." PLOS ONE 8, no. 7 (2013): e123456. https://doi.org/10.1371/journal.pone.0123456.
8 FDA PMA P110006 summary of safety and effectiveness.
9 AI Assistant available third-party tools include QVCAD™, Koios DS™ Breast, BU-CAD™ and MONCAD ABS. Not available in all regions.
10 Compared to Invenia™ ABUS 2.0.
11 CEM guided biopsy can be performed within 15 minutes from first image to clip placement image. A shorter biopsy lead time and quicker biopsy procedure may speed up a definitive diagnosis and faster path to treatment. https://www.cedars-sinai.edu/Patients/Programs-and-Services/Imaging-Center/For-Patients/Exams-by-Procedure/MRI/MRGuided-Breast-Biopsy/MR-Guided-Breast-Needle-Core-Biopsy-Procedure-Information.aspx Data on file 2020, GE HealthCare.
12 Compared to without contrast
J. Sung et al., Radiology 2019; 00:1–8
V. Sorin et al. American Journal of Roentgenology: W267-W274. 10.2214/AJR.17.19355
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
CRWV vs. PLTR vs. NVDA: Which Is the Best AI Stock to Buy Now, According to Analysts?
The stock market remains volatile due to geopolitical tensions and macro uncertainty, raising concerns about a potential slowdown in AI (artificial intelligence) spending. Nonetheless, Wall Street remains confident about several AI stocks, given the massive growth opportunity in the generative AI space over the long term. Using TipRanks' Stock Comparison Tool, we placed CoreWeave (CRWV), Palantir Technologies (PLTR), and Nvidia (NVDA) against each other to find the best AI stock, according to Wall Street analysts. Confident Investing Starts Here: CoreWeave (NASDAQ:CRWV) Stock CoreWeave, a cloud provider that specializes in AI infrastructure, is experiencing strong traction for its offerings amid the ongoing AI boom. The company has been in the news for its strategic deals. Notably, CoreWeave struck a $11.9 billion 5-year cloud computing contract with ChatGPT-maker OpenAI. The two AI companies also signed an expanded agreement of up to $4 billion to meet the growing demand for high-performance computing. Furthermore, CoreWeave is reportedly powering the recently announced cloud deal between Alphabet's Google (GOOGL) and OpenAI. CRWV stock has rallied by a staggering 359% from its IPO (initial public offering) price of $40. Is CRWV a Good Stock to Buy? Recently, Bank of America analyst Bradley Sills downgraded CoreWeave stock to Hold from Buy on valuation concerns, following the stellar rally in the AI infrastructure stock in reaction to the Q1 earnings. The 4-star analyst highlighted that CRWV stock is trading at an elevated valuation of 2027 EV/EBIT (enterprise value-to-earnings before interest and taxes) of 25x. While Sills noted several positives, like the expansion of CoreWeave's partnership with OpenAI and impressive revenue momentum, he pointed out the company's huge capital expenditure ($46.1 billion through 2027). Consequently, the analyst expects $21 billion of negative free cash flow through 2027. Turning to Wall Street, CoreWeave stock scores a Moderate Buy consensus rating based on six Buys, 11 Holds, and one Sell recommendation. The average CRWV stock price target of $78.53 indicates a significant downside risk of 57.2% from current levels. Palantir Technologies (NASDAQ:PLTR) Stock Data analytics company Palantir Technologies is considered one of the hottest AI stocks. PLTR stock has rallied more than 81% so far in 2025. The company's revenue is growing at a rapid pace across its Government and Commercial businesses. Palantir's AIP (Artificial Intelligence Platform) offering is bolstering its business. Palantir's market-beating first-quarter results reinforced the strength of its AI-powered offerings. Notably, Q1 2025 revenue increased by 39% year-over-year to $884 million, while adjusted EPS (earnings per share) jumped 62%. Additionally, the company raised its full-year guidance, as it believes that it is in the 'middle of a tectonic shift' in the adoption of its software, mainly in the U.S. Is Palantir Stock a Buy? While several analysts are cautious on Palantir stock due to its lofty valuation, Loop Capital analyst Mark Schappel reiterated a Buy rating and boosted the price target from $130 to a Street-high of $150. Following a meeting with management, the 5-star analyst stated that he is more convinced about PLTR's AI growth story and his bullish investment thesis. Schappel believes that Palantir is an early software leader in enterprise AI, which he thinks is at a 'tipping point,' as small-scale pilots move into production and AI use cases increase exponentially across all industries. Trading at 48x EV/2027 revenue, the analyst agrees that PLTR stock is 'not for the faint of heart.' That said, he contends that investors should look at the big picture, which indicates that Palantir is exposed to a massive AI opportunity. With 10 Holds, three Buys, and four Sells, Wall Street has a Hold consensus rating on Palantir Technologies stock. The average PLTR stock price forecast of $104.27 indicates a possible downside of 24.1% from current levels. Nvidia (NASDAQ:NVDA) Stock After a tough start to the year due to concerns about rising competition in the AI space, chip export restrictions, and tariff woes, Nvidia stock has recovered 21% over the past three months and is up 7.1% year-to-date. While uncertainty around chip exports and competition from custom AI chips remain an overhang, the semiconductor giant continues to gain from robust demand for its GPUs (graphics processing units) in the AI space, as reflected in the market-beating first-quarter results. Looking ahead, the demand for NVDA's Blackwell platform is expected to boost its top-line growth. Moreover, the company's focus on 'sovereign AI,' which it defines as a country's ability to develop and deploy AI, could drive its revenue higher. In this regard, Nvidia's lucrative deals, like the recently announced agreement with Saudi Arabia and Germany, are worth noting. Is Nvidia Stock a Buy, Hold, or Sell? Earlier this month, Bank of America Securities analyst Vivek Arya reiterated a Buy rating on Nvidia stock with a price target of $180. Following a meeting with management, the 5-star analyst noted that the tone of the team was very positive regarding demand for Nvidia's products and continued customer interest across cloud and enterprise, backed by a full-scale supply ramp. Arya believes that management addressed three key investor debates that have been weighing on NVDA stock over the past year – Blackwell rack ramp and execution, AI diffusion and sovereign demand, and China AI shipments. The analyst stated that Nvidia stock remains a top sector pick for Bank of America, as it is 'best positioned' to benefit from the ongoing AI boom, bolstered by a multi-year lead in 'performance (AI scaling), pipeline, incumbency, scale, and developer support.' Despite near-term challenges, Wall Street has a Strong Buy consensus rating on Nvidia stock based on 35 Buys, four Holds, and one Sell recommendation. The average NVDA stock price target of $173.19 indicates 20.4% upside potential from current levels. Conclusion Wall Street is highly bullish on Nvidia stock, cautiously optimistic on CoreWeave, and sidelined on Palantir stock. Currently, analysts forecast further upside in chip giant Nvidia's stock while they see possible downside risk in the other two AI stocks. The optimism of most analysts on Nvidia stock is backed by its strong fundamentals, robust demand for its AI chips, continued innovation, and solid execution.
Yahoo
an hour ago
- Yahoo
Slide Insurance (SLDE) Skyrockets 15% on Strong Investor Confidence
Slide Insurance Holdings, Inc. (NASDAQ:SLDE) is one of the Slide Insurance rallied by 15.06 percent on Friday to close at $23.30 apiece, its second day as a publicly listed company, reflecting strong investor confidence. Under its upsized initial public offering (IPO), Slide Insurance Holdings, Inc. (NASDAQ:SLDE) offered 24 million shares at a price of $17 apiece, potentially raising $408 million in fresh funds. Of the total, 16.6 million shares were offered by the company, while the remaining 7.3 million shares were sold by certain stockholders. Slide Insurance Holdings, Inc. (NASDAQ:SLDE) also granted the underwriters a 30-day option to acquire up to 3.6 million shares. A woman in a business suit in an insurance office, analyzing a policy. Slide Insurance Holdings, Inc. (NASDAQ:SLDE) is a technology-enabled property insurance company that offers customizable coverage options that suit their unique needs and budgets. While we acknowledge the potential of SLDE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Business Upturn
2 hours ago
- Business Upturn
LPRO DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Open Lending Corporation Investors to Secure Counsel Before Important June 30 Deadline in Securities Class Action
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) — WHY: New York, N.Y., June 21, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporation (NASDAQ: LPRO) between February 24, 2022 and March 31, 2025, both dates inclusive (the 'Class Period'), of the important June 30, 2025 lead plaintiff deadline. SO WHAT: If you purchased Open Lending securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Open Lending class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose materially adverse facts about Open Lending's business, operations, and prospects. Specifically, defendants: (1) misrepresented the capabilities of Open Lending's risk-based pricing models; (2) issued materially misleading statements regarding Open Lending's profit share revenue; (3) failed to disclose Open Lending's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; (4) misrepresented the underperformance of Open Lending's 2023 and 2024 vintage loans; and (5) as a result of the foregoing, defendants' positive statements about Open Lending's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Open Lending class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
